One Technology with multiple platforms, for consistent performance across every level of your organization.

The Drug Discovery Process

PMs can be applied at multiple stages in the drug discovery process, providing researchers with better information to help make better decisions. With PMs the entire process becomes faster and more efficient.

The current drug discovery and development process is long and expensive. Just consider:

  • Only one compound of 10,000 makes it to market
  • It can take upwards of 15 years and $800 million to commercialize a single drug

The challenge for drug companies is three-fold: reduce product development costs… decrease time to market… and increase the probability of success for the most promising leads. Biolog's PM technology can assist with these three challenges — and more.

Figure 1

The genomic revolution has delivered massive amounts of data about life's molecular components, moving the bottleneck in drug discovery downstream by giving drug discovery organizations more qualified targets and leads than ever before. However, there remains a barrier in going from molecular data to understanding what really happens in living cells. PMs provide the needed technology to complement molecular genomics and cross that barrier (see diagram below).

Figure 2

Just as genomics and proteomics have made it possible to measure levels of sounds of genes and proteins all at once, Biolog's new PM technology can quantitatively measure thousands of cellular phenotypes in one analysis. This provides the technological transition over the barrier from molecular to cellular analysis.

Impact on the Drug Discovery Process

Continuing innovations in genomics and analytical technologies have made it particularly difficult for pharmaceutical and biotechnology organizations to determine the optimum approach to employ in the drug discovery process. Biolog has demonstrated that Phenotype MicroArray technology has the ability to deliver significant benefits at multiple stages in the drug discovery process:

  • Permits direct cellular assay of gene function
  • Complements genetic and molecular methods and extends existing gene expression data
  • Provides analysis of genetic mutations
  • Identifies metabolic pathways and may include enzyme specific targeting
  • Allows efficient evaluation of drug leads
  • Allows direct observation of a drug's primary and secondary effects at the cellular level
  • Reduces need for expensive, slow animal / plant models

The result of using PM technology? More promising druggable leads and a reduction in failure rates. PMs help drug companies to choose the right drug leads for animal and human testing, saving time and money by lowering the opportunity cost associated with bad decisions.

Brochure on Using PM Technology in Drug Discovery
To view a document providing an overview of PM technology applied to drug discovery click here to view and download a pdf file.

Mechanism of Action (MOA) of Antimicrobials
To view a document on Using PM Technology in Antimicrobial MOA Studies click here to view and download a pdf file.

Structure Activity Relationship (SAR) Analysis
To view a document on Using PM Technology to Guide SAR Studies click here to view and download a pdf file.